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Background: Infection is the leading cause of morbidity and the second most frequent cause of mortality among
patients on renal replacement therapy. A major morbid event in this population is hospitalization because of
infection. The aim of this study was to investigate the risk factors for morbidity and mortality related to bloodstream
infection (BSI) among patients on hemodialysis.
Results: Risk factors for morbidity and mortality related to BSI in patients on hemodialysis were investigated
retrospectively by nested case–control, from January 2010 to June 2013. Patients were divided into two
groups: those who progressed to hospitalization or death due to BSI (Group 1) and those who developed BSI,
but did not progress to the same outcome (Group 2). Data were collected through consultation of patient records.
For statistical analysis, logistic regression was used. There were 32 patients in Group 1 and 61 in Group 2. Logistic
regression verified that, for each year of age, the chance of death or hospitalization for BSI increased 1.05 times
[95% confidence interval (CI): 1.02–1.09]. Patients with BSI caused by Staphylococcus aureus had an 8.67 times
higher chance of progressing to death or hospitalization (95% CI: 2.5–30.06). The isolation of multiresistant
microorganisms in blood cultures of hemodialysis patients increased morbidity and mortality by 2.75 times
(95% CI: 1.01–7.48).
Conclusion: Independent risk factors for morbidity and mortality among patients after developing BSI during
hemodialysis were: age, blood culture positive for S. aureus, and antibiotic resistance. Control measures to
prevent microbial dissemination, primarily the multiresistant ones, should be intensified in this population.
More studies are needed to standardize specific measures not yet classically standardized, such as collection
of surveillance culture samples, contact precautions, and decolonization.
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Infection is the leading cause of morbidity and the sec-
ond most frequent cause of mortality among patients on
renal replacement therapy [1].
North American data show that rates of bloodstream in-
fection (BSI) in hemodialysis patients range from 0.5 to
27.1/100 patients/month, depending on the type of access
used [2]. More recent studies demonstrated a reduction* Correspondence: dayana.fram@unifesp.br
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unless otherwise stated.in the incidence of BSI in this population from 1.09
to 0.89/100 patients/month and from 2.04 to 0.75/100
patients/month after implementation of specific con-
trol measures [3,4].
According to the US Renal Data System, one of the
principal morbidity events in patients receiving renal re-
placement therapy is hospitalization because of infection,
which increased by 43% between 1993 and 2011, con-
trasting with hospitalization for complications of venous
access that were found to decrease by 57% [1]. The same
study showed that the mortality rate at the end of the first
year of hemodialysis decreased by 38% for cardiovasculard. This is an Open Access article distributed under the terms of the Creative
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2010. All-cause mortality fell from 440 to 201 deaths/
1000 patients/year, and for infectious diseases, the mor-
tality rate decreased from 43 to 19.4 deaths/1000 patients/
year [1].
Despite all measures to prevent BSI specifically in
hemodialysis patients, this event continues to have a sig-
nificant impact on the progression of these patients [5-8].
Most authors have shown that, among the microorgan-
isms isolated in blood cultures of hemodialysis patients,
28–65% are Gram positive, and Staphylococcus aureus
is the most frequent, and ∼ 45% are Gram negative [9-11].
Gram-positive microorganisms, mainly S. aureus, are as-
sociated with higher rates of mortality; primarily when
resistant to methicillin (methicillin-resistant S. aureus;
MRSA). The presence of septic shock and polymicrobial
infections are related to higher mortality in this popula-
tion [12,13].
Several studies [14,15] have examined the main risk
factors for the development of BSI. The results of these
studies have led to improved preventive measures, which
may have caused a decrease in morbidity and mortality
in this population. However, few studies [11] have ana-
lyzed the risk factors for morbidity and mortality in pa-
tients with end-stage renal disease (ESRD) who have
already developed this complication.
The occurrence of adverse events, such as mortality and
hospitalization, and frequent exposure to invasive proce-
dures in the population susceptible to ESRD, motivated
the present study, which aimed to identify risk factors for
morbidity and mortality related to BSI.
Methods
Ethical aspects
The study received approval from the Committee on
Ethics in Research of the Universidade Federal de São
Paulo.
Design, period and location of study
This was a retrospective nested case–control study, which
investigated the prevalence of BSI during January 2010
to June 2013. This study was developed in an outpatient
hemodialysis unit of the Hospital do Rim e Hipertensão
da Fundação Oswaldo Ramos, São Paulo, Brazil. About
400 patients attend the dialysis program every month.
There were 353 patients in the dialysis program during
the study; 221 (63%) were on hemodialysis and 132 (37%)
on peritoneal dialysis. This institution follows rigorous
norms for the completion of patient records.
Patients
We included only hemodialysis patients with ESRD, inde-
pendent of treatment duration, aged ≥18 years, with posi-
tive blood culture, and conforming to specific criteriafrom the US Centers for Disease Control and Prevention
(CDC) [16]. The blood cultures were processed according
to the recommendations of the Clinical and Laboratory
Standards Institute (CLSI) [17].
The patients were identified through a review of the
reports of the microbiology laboratory, and only the first
episode of BSI was considered. From a total of 221 pa-
tients on hemodialysis, 93 (42.1%) had BSI and met the
inclusion criteria, and were divided into two groups. Pa-
tients who progressed to hospitalization or death were
classified as Group 1. Patients who did not have the same
progression were classified as Group 2. Hospitalization
was considered to be related to BSI when patients were
hospitalized for treatment of BSI, and death was consid-
ered related to BSI when it occurred within 15 days after
microbiological diagnosis of infection [18,19].
Study protocol and data collection
After selecting the patients, data collection was con-
ducted through consultation of the medical records. The
following sociodemographic characteristics were recorded:
age, sex, race, and educational level. The following clinical
variables were recorded: comorbidity (defined by phys-
ician diagnosis reported in the medical records at patient
admission to the hospital for hypertension, cardiovascular
diseases, diabetes mellitus and other diseases); previous
treatment for ESRD (patients may have undergone more
than one type of treatment before the study, e.g., conser-
vative treatment, peritoneal dialysis, hemodialysis and
transplantation); body mass index (BMI) [20]; number of
transfusions; use of previous antimicrobial agents; ad-
equate empiric antibiotic therapy; previous hospitalization;
number of previous hospitalizations. We also recorded
variables related to hemodialysis (length of treatment,
type, location and length of current venous access), and
number of previous venous accesses), average values of la-
boratory tests, microorganisms isolated in blood culture,
antibiotic resistance profile, and death. The variables were
recorded for up to 6 months before BSI.
Empirical therapy was considered adequate when the
microorganisms isolated in blood culture were sensitive
to the antimicrobial agent used [11,21]. The microorganisms
were considered to be multiresistant when they showed
resistance to at least one agent in three or more antimicro-
bial classes. Staphylococcus was considered multiresistant
when it was not susceptible to methicillin (methicillin-
resistant S. aureus; MRSA), and Enterococcus when it
showed resistance to vancomycin [22,23].
Statistical analysis
A descriptive analysis was conducted of the patients who
were hospitalized or progressed to death due to BSI
(Group 1) versus patients who did not progress to these
outcomes (Group 2). Sociodemographic, clinical and
Table 1 Sociodemographic characteristics and clinical
variables of the patients
Group 1 Group 2
n = 32 n = 61 p
Age 62 ± 17.8 53 ± 17.5 0.027
Sex
Male 16 (50.0) 25 (41.0) 0.405
Female 16 (50.0) 36 (59.0)
Race
White 22 (69.0) 34 (55.7) 0.223
Non-white 10 (31.0) 27 (44.3)
Educational level
No education 10 (31.2) 15 (24.6) 0.757
Elementary 12 (37.5) 20 (32.8)
High school 7 (21.9) 18 (29.5)
Higher education 3 (9.4) 8 (13.1)
Comorbidity
Hypertension 30 (93.8) 49 (80.3) 0.127
Cardiovascular diseases 8 (25.0) 12 (19.7) 0.552
Diabetes mellitus 15 (47.0) 18 (29.5) 0.096
Othera 12 (37.5) 20 (32.8) 0.650
Previous treatment 20 (62.5) 43 (70.5) 0.434
Type of previous treatment
Conservative 14 (43.8) 28 (46.0) 0.843
Peritoneal dialysis 6 (18.8) 15 (24.6) 0.522
Hemodialysis 5 (15.6) 13 (21.3) 0.510
Transplant 5 (15.6) 11 (18.0) 0.770
Body mass index (kg/m2) 24.8 ± 4.7 24.0 ± 4.4 0.374
Transfusions 1 (3.1) 10 (16.4) 0.090
No. of transfusions 1 (-) 2 ± 2.7
Use of previous antimicrobials 15 (47.0) 19 (31.1) 0.135
Adequate empiric antibiotic therapy 24 (75.0) 51 (83.6) 0.318
Previous hospitalization 7 (21.9) 12 (19.7) 0.802
No. of previous hospitalizations 1.4 ± 0.5 1.5 ± 1.5 0.297
Values expressed as mean ± SD or n (%).
aHypothyroidism, hyperthyroidism, neoplasia, or systemic lupus erythematosus.
Fram et al. BMC Research Notes 2014, 7:882 Page 3 of 8
http://www.biomedcentral.com/1756-0500/7/882laboratory variables, and parameters related to treatment
were considered. The data were presented using absolute
frequencies and percentages, means, standard deviations
and medians (25th–75th percentile), when appropriate.
The primary outcome was death or hospitalization re-
lated to BSI (morbidity and mortality). The association
between the primary outcome and the categorical vari-
ables was tested with the χ2 test, Fisher’s exact test, or
the likelihood ratio. The association between continuous
variables and the primary outcome was determined using
Student’s t test, Mann–Whitney test and analysis of vari-
ance, as appropriate.
Univariate logistical regression was used to investigate
the relationship of each independent variable with the
dependent variable (death or hospitalization due to BSI).
The variables with p ≤ 0.05 were selected for further ana-
lyses. The independent variables tested in univariate ana-
lyses were: sociodemographic characteristics, type and
characteristics of hemodialysis access, laboratorial vari-
ables, and microbiological aspects of the microorganisms
isolated. Multiple logistic regression was used to deter-
mine the independent variables that continued to be as-
sociated with morbidity and mortality. To include the
variables in the regression model, the forward stepwise
method was used. The odds ratios (ORs) were calculated
with the respective 95% confidence intervals (CIs).
SPSS version 19.0 was used for statistical analysis (Chicago,
IL USA).
Results
There were 221 patients in the hemodialysis program dur-
ing the study period and 93 (42.1%) met the inclusion cri-
teria for the study. Of these, 32 (34.4%) progressed to
death within 15 days of infection or were hospitalized for
treatment of the infection (Group 1). Among the 32 pa-
tients, seven (22.0%) died, and 25 (78.0%) were hospital-
ized for treatment of BSI. Seventy-one patients (65.6%)
did not have the same outcomes (Group 2).
Table 1 shows the sociodemographic and clinical char-
acteristics of the patients evaluated. There was no sig-
nificant difference between the groups, except for the
variable of age (p = 0.028), which was significantly higher
in Group 1.
There was no significant difference between the groups
for variables related to hemodialysis (Table 2).
Table 3 presents the results of laboratory tests for each
group. The average leukocyte count in Group 1 was sig-
nificantly higher compared with Group 2.
Table 4 shows the microorganisms isolated in blood
culture. Among the microorganisms isolated from pa-
tients in Group 1, Gram-positive bacteria represented
84.3% (n = 27), and 55.6% were multiresistant, and Gram-
negative bacteria accounted for 15.7% (n = 5) with
80% showing multiple resistance. The most frequentmicroorganism was S. aureus (50%; n = 16), and 43.8%
of these were multiresistant. There were no fungi iso-
lated in Group 1. Among the microorganisms isolated
from patients in Group 2, 67.2% (n = 41) were Gram-
positive bacteria and 41.5% were multiresistant, and 31.2%
(n = 19) were Gram-negative bacteria, and 15.8% were
multiresistant. Fungi accounted for 1.6% of the isolates.
Table 5 shows the statistical analysis of the isolated
microorganisms. The variables S. aureus and multiresis-
tant microorganisms were statistically significant (p ≤
0.05) in the initial analysis and were selected for logistic
regression.
Table 2 Variables related to hemodialysis treatment
Group 1 Group 2
n = 32 n = 61 p
Length of hemodialysis treatment (mo) 16 (4.5–0.5) 11 (3.0–0.8) 0.771
Type of current access
AVF 12 (37.5) 15 (24.6) 0.097
CVC (long duration) 20 (62.5) 42 (68.9)
CVC (short duration) 0 (-) 4 (6.6)
Location of current venous access
Jugular vein 17 (53.1) 42 (68.9) 0.308
Subclavian vein 4 (12.5) 4 (6.6)
Upper arm 11 (34.4) 15 (24.6)
Duration of current venous access
1–30 d 6 (18.8) 15 (24.6) 0.533
30–180 d 9 (28.1) 21 (34.4)
> 180 d 17 (53.1) 25 (41.0)
Previous venous access (6 mo) 8 (25.0) 23 (37.7) 0.217
No. of previous accesses 1.1 ± 0.38 1.2 ± 0.39 0.853
Values expressed in mean ± SD, n (%) or median (25th–75th percentile).
AVF: arteriovenous fistula.
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Table 6. In the univariate analysis, the variables signifi-
cantly associated with morbidity and mortality were: age,
S. aureus and multiresistant microorganisms. All of the
significant variables in the univariate analysis were inde-
pendent risk factors for morbidity and mortality among
patients in the multivariate analysis. For each year of age
increase, the chance of death or hospitalization due to
BSI increased 1.05 times (95% CI: 1.02–1.09). Patients
with BSI caused by S. aureus had 8.67 times more
chance of progression to death or hospitalization (95%Table 3 Average values of laboratory tests for each group
Group 1 Group 2
n = 32 n = 61 p
Urea (mg/dL) 140 (45.1) 147 (31.6) 0.399
Creatinine (mg/dL) 8.4 (2.7) 9.3 (2.8) 0.152
Kt/V 1.4 (0.3) 1.4 (0.3) 0.439
Alkaline phosphatase (U/L) 74.5 (65.3-46.0) 82.3 (70.0-47.5) 0.241
Ferritin (mg/L) 705 (385.9) 573 (314.3) 0.094
Leukocyte (cells/mm3) 9038 (3083) 7582 (2362) 0.017
Hemoglobin (g/dL) 11.1 (1.4) 10.6 (1.5) 0.123
Hematocrit (%) 33.7 (4.6) 32 (4.9) 0.105
Albumin (g/dL) 3.7 (3.4-3.1) 3.7 (3.5-2.9) 0.425
Anti-HCV negative 31 (96.9) 61 (100) 0.165
Anti- HBs negative 30 (93.8) 57 (93.44) 0.954
Values expressed in mean ± SD, n (%) or median (25th–75th percentile).
HBs, hepatitis B surface antigen; HCV, hepatitis C virus; Kt/V, parameter used for
measurement of the adequacy of hemodialysis treatment.CI: 2.5–30.06) in relation to BSI caused by other micro-
organisms. The isolation of multiresistant microorgan-
isms in the blood cultures of hemodialysis patients
increased morbidity and mortality by 2.75 times (95%
CI: 1.01–7.48) when compared with the isolation of sen-
sitive organisms.
Discussion
The present study evaluated the risk factors for morbid-
ity and mortality in patients with BSI undergoing
hemodialysis.
Rojas et al. [24] conducted a retrospective cohort
study in the nephrology department of a Spanish teach-
ing hospital to evaluate the risk factors for mortality and
other unfavorable outcomes in patients with BSI. Age
was one of the risk factors associated with mortality
(p = 0.02). Hospitalization was not evaluated, and the
study also included all patients undergoing renal replace-
ment therapy and not just specifically hemodialysis as in
the current study. Another retrospective study, conducted
in a Swiss university hospital, evaluated outcomes of two
groups of older patients on hemodialysis, divided by age
range (60–69 and ≥70 years) and did not find any signifi-
cant differences in relation to all-cause mortality (p = 0.07)
and hospitalization (p = 0.06) [25].
The current study showed that age was related to mor-
bidity and mortality, and for every annual increase in
age, the chance of death or hospitalization due to BSI in-
creased 1.05 times (95% CI: 1.02–1.09).
S. aureus is associated with high mortality rates, espe-
cially MRSA [12,13]. Engemann et al. [26] conducted a
prospective study in a North American university hos-
pital over a 7-year period. They followed 210 patients
undergoing hemodialysis who were hospitalized for BSI
with S. aureus. All-cause mortality rate was 19% (n = 40)
compared with 10.5% (n = 22) for BSI with S. aureus.
Danese et al. [27] conducted a retrospective cohort
study in the US to evaluate first hospitalization for BSI
in patients in the first year of hemodialysis. They showed
that BSI caused by S. aureus, when compared with BSI
caused by other microorganisms, was associated with
17% higher mortality (OR: 1.17, 95% CI: 1.08–1.26).
In the present study, BSI with S. aureus was re-
lated to an increase of 8.67 times in the chance of
patients progressing to death or hospitalization (95%
CI: 2.5–30.06) when compared with BSI caused by
other microorganisms.
The majority of the studies evaluated morbidity and
mortality among patients with BSI caused by MRSA or
methicillin-sensitive S. aureus (MSSA). In a retrospective
study, FitzGerald et al. [13] demonstrated a significant
difference between the proportion of deaths that oc-
curred in patients with BSI caused by MRSA compared
with MSSA (p < 0.01).
Table 4 Microorganisms isolated in blood cultures and profile of resistance
Group 1 Group 2
n = 32 n = 61
MR S Total MR S Total
Gram positive
S. aureus 7 (43.8) 9 (56.2) 16 (50.0) 5 (33.3) 10 (66.7) 15 (24.6)
Othersa 8 (72.7) 3 (27.3) 11 (34.3) 12 (46.2) 14 (53.8) 26 (42.6)
Total 15 (55.6) 12 (44.4) 27 (84.3) 17 (41.5) 24 (58.5) 41 (67.2)
Gram negative
Enterobacteriaceae 3 (75.0) 1 (25.0) 4 (12.5) 1 (11.1) 8 (88.9) 9 (14.8)
Non-fermenters 1 (100.0) 0 (-) 1 (3.2) 2 (20.0) 8 (80.0) 10 (16.4)
Total 4 (80.0) 1 (20.0) 5 (15.7) 3 (15.8) 16 (84.2) 19 (31.2)
Fungi
Candida albicans 0 (-) 0 (-) 0 (-) 0 (-) 1 (100.0) 1(1.6)
Values expressed as mean ± SD or n (%).
aStreptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus pyogenes,Staphylococcus simulans, Staphylococcus
warneri, Staphylococcus epidermidis, Staphylococcus capitis, coagulase-negative Staphylococcus, Staphylococcus haemolyticus, Staphylococcus lugdinensis and
Enterococcus faecalis.
MR: multiresistant, S: sensitive.
Fram et al. BMC Research Notes 2014, 7:882 Page 5 of 8
http://www.biomedcentral.com/1756-0500/7/882Conterno et al. [18] performed a nested case–control
study to identify risk factors for mortality for BSI caused
by S. aureus, and showed a mortality risk 4.2 times higher
among patients who developed MRSA bacteremia when
compared with the patients that developed bacteremia
due to MSSA. Surveillance data on MRSA from the CDC
showed that 90% of patients on hemodialysis or periton-
eal dialysis, who developed BSI caused by MRSA, wereTable 5 Initial statistical analysis of the microorganisms
isolated in the groups
Group 1 Group 2 p
n = 32 n = 61
Gram staining
Positive 27 (84.4) 41 (67.2) 0.095
Negative 5 (15.6) 19 (31.1)
Comparison between microorganisms
S. aureus 16 (50.0) 15 (24.6) 0.014
Other microorganisms 16 (50.0) 46 (75.4)
S. aureus 16 (50.0) 15 (24.6) 0.066
Other Gram-positive organisms 11 (34.4) 26 (42.6)
Enterobacteriaceae 4 (12.5) 9 (14.8) 0.327
Non-fermenters 1 (3.1) 10 (16.4)
Resistance profile
Multiresistant 19 (59.4) 20 (32.8) 0.014
Sensitive 13 (40.6) 41 (67.2)
Gram-positive multiresistant 15 (46.9) 17 (27.9) 0.255
Gram-positive sensitive 12 (37.5) 24 (39.3)
S. aureus multiresistant 7 (21.9) 5 (8.2) 0.552
S. aureus sensitive 9 (28.1) 10 (16.4)hospitalized, and the rate of MRSA-related mortality was
17% [28]. Another study that evaluated the progression
of hemodialysis patients who developed BSI caused by
MRSA or MSSA demonstrated similar mortality between
the two groups (30.9 and 32.1%, respectively) [29].
Data from the present study demonstrated that multi-
resistant microorganisms isolated in blood culture from
hemodialysis patients increased morbidity and mortality
by 2.75 times (95% CI: 1.01–7.48) when compared with
the isolation of sensitive microorganisms. There are no
data in the literature comparing morbidity and mortality
among patients with BSI caused by any multiresistant
microorganism and patients who developed BSI caused
by susceptible microorganisms.
According to several authors [11,14,15], the use of short-
duration central venous catheter (CVC) and a new vascu-
lar access are important risk factors for BSI. However,






OR (95% CI) p OR (95% CI) p
Age 93 1.03 (1.00–1.06) 0.031 1.05 (1.02–1.09) 0.004
Microorganisms 93
S. aureus (31) X other
microorganisms (62)






3.00 (1.24–7.26) 0.015 2.75 (1.01–7.48) 0.047
X: versus.
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BSI. The presence, time of use, and type of catheter
were not risk factors for the outcomes studied. The
use of short-duration CVC is not common in patients
with ESRD, given that only four patients included in
our study used this device and, all belonged to Group 2.
Long-duration CVC was used in both groups (20 in
Group 1 and 42 in Group 2), also without statistical sig-
nificance between the groups.
We demonstrated that risk factors for morbidity and
mortality among patients with BSI on hemodialysis were:
age, isolation of S. aureus, and isolation of a resistant
microorganism. The result reinforces the need to imple-
ment specific control measures to decrease the spread of
multiresistant microorganisms in this population.
The control of the dissemination of S. aureus in
hemodialysis patients, along with general measures of
infection control, requires other specific measures. For
example, Sesso et al. [30] showed in a prospective ran-
domized study that administration of mupirocin at the
CVC insertion site in hemodialysis patients signifi-
cantly reduced the risk of colonization and bacteremia
by S. aureus. In a recent systematic literature review
and meta-analysis, Taminato et al. [31] demonstrated
that mupirocin is effective for reduction of BSI caused
by S. aureus.
Preventive measures that are already standardized
should be intensified and controlled through vigilance,
including: surveillance of infection, education of health
professionals, hand washing, use of personal protective
equipment, environmental cleaning, maximization of
barriers to insertion of CVC, use of skin antisepsis before
catheter insertion and dressing changes, inspection of the
CVC insertion site, protection of CVC, and replacing the
catheter-site dressing when it becomes damp, loosened or
soiled, [4,5,8,32].
The positive deviance (PD) to engage the staff has
been used to reduce BSI in outpatient hemodialysis cen-
ters [33]. PD consists of a social and behavioral change
process to deal with matters. This process is based on
the fact that in institutions there are groups or individ-
uals with different (deviant) practices that achieve posi-
tive results when compared with co-workers with the
same resources [34]. PD has been successfully applied in
different countries to reduce infection by multiresistant or-
ganisms, surgical site infection, and improve hand hygiene
adherence [35-37]. Strategies that are not yet classically
recommended, such as collection of surveillance cultures,
decolonization and contact barriers, require more studies
to demonstrate their effectiveness [38,39].
With regard to the limitations of the current study,
these were inherent in the retrospective character of the
data collection. However, the medical records of the pa-
tients in our institution were completed with great care,due to the characteristics of being a service dedicated to
the treatment of chronic renal patients, which follows
the directives of the organization. Additionally, there
were standardized protocols for the performance of blood
cultures in these patients and it was unlikely that these
events were underdiagnosed during the study.
Conclusions
Risk factors for morbidity and mortality among patients
with BSI undergoing hemodialysis were: age, isolation of
S. aureus, and isolation of resistant microorganisms. The
results of this study emphasize the importance of invest-
ment in prevention and control of the dissemination of
microorganisms; mainly multiresistant microorganisms
that were associated with greater morbidity and mortal-
ity in this population. Process measures can be a useful
tool for the control of already standardized protocols.
More studies are needed to standardize additional mea-
sures of prevention.
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